Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05748600 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

Study acronym: EXHALE-4
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 321 to 335v17
  2. Enrollment target: 550 to 600v16
  3. Study sites: 314 to 321v15
  4. Study sites: 243 to 314
    • Primary completion date: Mar 2025 to Sep 2025
    • Study completion date: Apr 2025 to Dec 2025
    v14
  5. Study sites: 239 to 243v13
Show 11 earlier versionsHide 11 earlier versions
  1. Study sites: 196 to 239v12
  2. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 209 to 196
    v11
  3. Study sites: 117 to 209v10
  4. Primary completion date: Jun 2024 to Mar 2025
    • Study completion date: Jul 2024 to Apr 2025
    v9
  5. Study sites: 94 to 117v8
  6. Enrollment target: 750 to 550
    • Study sites: 82 to 94
    • Eligibility criteria expanded, about 119 words
    • Secondary endpoints revised (7)
    v7
  7. Study sites: 68 to 82v6
  8. Study sites: 59 to 68v5
  9. Study sites: 44 to 59v4
  10. Study sites: 8 to 44
    • Secondary endpoints revised (7)
    v3
  11. Study title shortened, about 2 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma to evaluate improvements in lung function, asthma control, and quality of life. In addition, the study will further evaluate the safety and tolerability of dexpramipexole in participants with eosinophilic asthma.
Trial Details
NCT Number NCT05748600
Lead Sponsor Areteia Therapeutics
Conditions
(from sponsor)		 Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack
Related terms Asthma, Pulmonary Eosinophilia
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov